ArticleFrontiers in oncology2025
Current trends and future projection for addressing the burden of esophageal carcinoma in Asia: a comprehensive analysis (1990-2040).
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparisons of the Burden and Quality of Care of Nonrheumatic Valvular Heart Disease in Asia and Globally.Journal of the American Heart Association · 2026Article
- Perioperative circulating tumor DNA profiling for recurrence risk in esophageal squamous cell carcinoma: moving toward a biology-driven surveillance model.Annals of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal carcinoma (EC) significantly impacts global health, particularly in Asia, where many low- and middle-income countries face substantial burdens despite advancements in some regions. Objective: This study analyzed EC's spatial and temporal distribution in Asia using the Global Burden of Disease (GBD) database, aiming to forecast future burdens and support effective prevention strategies. Methods: Data from 48 Asian countries (1990-2021) were extracted from the GBD database, covering incidence, prevalence, deaths, disability-adjusted life years (DALYs), risk factors, and socio-demographic index (SDI). R and GraphPad Prism were used to assess changes and predict future trends. Results: From 1990 to 2021, EC's disease burden in Asia generally declined, with significant regional and sex disparities. East Asia showed the most improvement despite having the highest burden. Conversely, South and Southeast Asia experienced limited progress, with some areas seeing increased burdens. Males consistently had higher burdens than females, especially in East Asia. Future projections (from 2022 to 2040) suggested a slight rise in incidence in East Asia, while improvements in South and Southeast Asia may remain limited, though an overall burden decline was expected. Conclusion: The reduction in Asia's EC burden underscored the impact of medical advances and public health efforts, but regional and sex disparities persist. Future strategies should enhance health resources in under-resourced and high-risk areas and implement targeted policies to address health inequalities and promote balanced public health development across Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.